Technical analysis of Abivax S.A. (ABVX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Price Performance
| 1 month | -7.43% |
| 3 months | -34.68% |
| Year-to-date | -37.03% |
| 1 year | -13.92% |
| 3 years | +740.69% |
52-Week Range
| 52-week High | $148.83 |
| 52-week Low | $69.81 |
| Avg Volume (90d) | 1.3M |
Technical Indicators
| SMA 50 | $99.53 |
| SMA 200 | $113.94 |
| Beta | -0.10 |
| 30-day Volatility (annualised) | 47.5% |
| Price vs SMA 50 | -14.7% |
| Price vs SMA 200 | -25.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $134.85 | |
| 2026-01 | $111.15 | -17.6% |
| 2026-02 | $121.28 | +9.1% |
| 2026-03 | $111.35 | -8.2% |
| 2026-04 | $117.38 | +5.4% |
| 2026-05 | $132.63 | +13.0% |
| 2026-06 | $133.26 | +0.5% |
| 2026-07 | $124.92 | -6.3% |
| 2026-08 | $111.73 | -10.6% |
| 2026-09 | $99.02 | -11.4% |
| 2026-10 | $86.59 | -12.6% |
| 2026-11 | $84.91 | -1.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-12-21 | $-0.92 | |
| 2026-09-21 | $-0.98 | |
| 2026-05-22 | $-1.07 | |
| 2026-03-23 | $-1.70 | $2M |
| 2025-12-15 | $-0.79 | $1M |
| 2025-09-08 | $-0.90 | $1M |
| 2025-06-02 | $-0.76 | $3M |
Price
| Price | $88.71 (closing price, November 3, 2026) |
| Market Cap | $7.8B |
| Exchange | NASDAQ |
| Country | FR |
Valuation Ratios
| Price / Book | 17.28 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.97 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 34.93 |